HFSA Virtual Board Certification Review 2020

General Meeting Information

Intended Audience

Learning Objectives

• Identify gaps in knowledge about advanced heart failure and transplant cardiology
• Focus study efforts on filling identified knowledge gaps
• Practice for the certification examination with ABIM-style multiple-choice test question
• -Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
• -Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
• -Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
• -Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
• -Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
• -Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
• -Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
• -Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device
• -Concise presentations by national experts will focus on blueprint content and will be augmented by board-review type questions posed using an audience-response system.

Topics ;

• 01 Heart Failure Epidemiology and Risk Factors
• 02 Pathophysiology I – Cellular and Energetic Considerations
• 03 Pathophysiology II – Hemodynamic, Structural, and Neurohormonal Considerations
• 04 Diagnosis and Clinical Assessment
• 05 Device Therapy in Heart Failure
• 06 Cardio-Oncology for the HF Boards
• 07 Clinico-Pathologic Correlates in Heart Failure_ Images for the Heart Failure Boards

Day 1

• 01 Welcome _ HFSA Introduction – Day 1
• 02 Advanced Heart Failure – Defining the Phenotype and Patient Selection for Advanced Therapies
• 03 Immunology – The Basics, PRA, Sensitization, Crossmatch
• 04 Rejection – Cellular and Antibody Mediated
• 05 Managing Immunosuppression and Drugs
• 06 Heart Transplant, Clinical Outcomes and Complications

Day 2

• Welcome _ Introductions – Day 2
• 01 Hemodynamics in HF I
• 02 Hemodynamics in HF II
• 03 Drug Therapy for Chronic HF I – Focus on Established Therapies
• 04 Drug Therapy for Chronic HF II – Focus on Newer Therapies
• 05 HFpEF – Epidemiology, Risk Factors, Diagnosis, Management (for the boards)
• 06 Management of the Hospitalized HF Patient
• 07 Management of Common Arrhythmias in HF (including AF)
• 08 Management of Comorbidities in Heart Failure
• 09 Specific Etiologies of HF I – Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)
• 10 Specific Etiologies of HF II – Inherited HF Syndromes (including HCM, ARVC, and LVNC)
• 11 Specific Etiologies of HF III – Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)
• 12 Adult Congenital Heart Disease for the HF Specialist
• 13 Q_A Panel I

Day 3

• Welcome _ Introductions – Day 3
• 01 Cardiogenic Shock Management
• 02 MCS I – Durable MCS Devices and Outcomes
• 03 MCS II – Temporary Support Devices and ECMO for the Boards
• 04 MCS III – MCS Complications and Patient Management
• 05 MCS IV – Troubleshooting (with HARVI)
• 06 Assessment of Functional Capacity Including Cardiopulmonary Exercise Testing
• 07 Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)
• 08 Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)
• 09 Pulmonary Hypertension
• 10 Q_A Panel II